Literature DB >> 12114452

Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.

Masaki Fujimura1, Takao Hidaka, Shigeru Saito.   

Abstract

The mechanism that regulates the growth of ovarian clearcell adenocarcinoma (CCA) are not well understood. We investigated the role of several growth factors that bind to membrane tyrosine kinase receptors and added them to the ovarian CCA cell lines KK, RMG-1, and HAC-II to evaluate their effect on growth and cellular invasion. Epidermal growth factor and transforming growth factor-alpha significantly stimulated the growth and invasion of CCA cell lines in vitro. ZD1839, an epidermal growth factor receptor-tyrosine kinase inhibitor, decreased the growth and invasion of CCA cell lines in vitro and in vivo inhibited the growth of xenografts of the CCA cell line RMG-1. Severe combined immunodeficient mice bearing RMG-1 xenografts treated with ZD1839 survived for longer than the untreated control group. From these findings, we conclude that ZD1839 may offer a new and effective treatment for ovarian CCA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12114452

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Authors:  Chandra Bartholomeusz; Tetsuro Oishi; Hitomi Saso; Ugur Akar; Ping Liu; Kimie Kondo; Anna Kazansky; Savitri Krishnamurthy; Jangsoon Lee; Francisco J Esteva; Junzo Kigawa; Naoto T Ueno
Journal:  Mol Cancer Ther       Date:  2011-12-05       Impact factor: 6.261

2.  Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Masami Hayashi; Kenjiro Sawada; Kimihiko Ito; Yoshito Terai; Yukihiro Nishio; Andres J Klein-Szanto; Robert A Burger; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

3.  A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.

Authors:  Edwin M Posadas; Meghan S Liel; Virginia Kwitkowski; Lori Minasian; Andrew K Godwin; Mahrukh M Hussain; Virginia Espina; Bradford J Wood; Seth M Steinberg; Elise C Kohn
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

Review 4.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

5.  mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Authors:  Seiji Mabuchi; Chiaki Kawase; Deborah A Altomare; Kenichirou Morishige; Kenjiro Sawada; Masami Hayashi; Masahiko Tsujimoto; Mareo Yamoto; Andres J Klein-Szanto; Russell J Schilder; Masahide Ohmichi; Joseph R Testa; Tadashi Kimura
Journal:  Clin Cancer Res       Date:  2009-08-18       Impact factor: 12.531

6.  Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin.

Authors:  Hideki Yamaguchi; Mike Lorenz; Stephan Kempiak; Corina Sarmiento; Salvatore Coniglio; Marc Symons; Jeffrey Segall; Robert Eddy; Hiroaki Miki; Tadaomi Takenawa; John Condeelis
Journal:  J Cell Biol       Date:  2005-01-31       Impact factor: 10.539

7.  Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer.

Authors:  Tong Ren; Ting-Ting Sun; Shu Wang; Jian Sun; Yang Xiang; Keng Shen; Jing-He Lang
Journal:  J Ovarian Res       Date:  2018-05-29       Impact factor: 4.234

8.  Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.

Authors:  Ting Zhao; Yu Shao; Yan Liu; Xiao Wang; Luyao Guan; Yuan Lu
Journal:  J Ovarian Res       Date:  2018-06-26       Impact factor: 4.234

9.  Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.

Authors:  S Okubo; J Kurebayashi; T Otsuki; Y Yamamoto; K Tanaka; H Sonoo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

Review 10.  Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.

Authors:  Shinya Matsuzaki; Kiyoshi Yoshino; Yutaka Ueda; Satoko Matsuzaki; Mamoru Kakuda; Akiko Okazawa; Tomomi Egawa-Takata; Eiji Kobayashi; Tadashi Kimura
Journal:  Cancer Cell Int       Date:  2015-12-15       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.